CSIMarket
 
Checkpoint Therapeutics inc   (CKPT)
Other Ticker:  
 
 
Price: $2.3200 $0.09 4.036%
Day's High: $2.34 Week Perf: 8.41 %
Day's Low: $ 2.20 30 Day Perf: 18.37 %
Volume (M): 569 52 Wk High: $ 5.54
Volume (M$): $ 1,321 52 Wk Avg: $2.44
Open: $2.25 52 Wk Low: $1.30



 Market Capitalization (Millions $) 46
 Shares Outstanding (Millions) 20
 Employees 19
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) 24
 Capital Exp. (TTM) (Millions $) 0

Checkpoint Therapeutics Inc
Checkpoint Therapeutics Inc. is a clinical stage biopharmaceutical company that focuses on the development of immunotherapy treatments for cancer. The company was founded in 2014 and is headquartered in New York City, USA. Checkpoint Therapeutics is a publicly traded company on the NASDAQ stock exchange with the ticker symbol "CKPT".

The company's primary focus is to develop treatments that enable the immune system to recognize and attack cancer cells by blocking two specific proteins: PD-L1 and VISTA. These proteins are frequently found on the surface of cancer cells, and they help the cancer cells evade detection by the body's immune system. If the immune system can't recognize the cancer cells, it can't attack them effectively, and the cancer cells continue to grow and spread.

Checkpoint Therapeutics is developing two lead drug candidates: CK-301 and CK-10 CK-301 is an anti-PD-L1 antibody that is entering Phase 3 clinical trials for non-small cell lung cancer, and CK-101 is an anti-PD-L1/VISTA bispecific antibody that is currently in Phase 1b clinical trials for advanced solid tumors.

In addition to its lead candidates, Checkpoint Therapeutics has a pipeline of additional immunotherapy treatments in preclinical development, including a bispecific antibody targeting PD-1 and LAG-3, and an agonistic antibody targeting CD40.

The company has a partnership with TG Therapeutics, Inc. for the development and commercialization of CK-301 in combination with TG's anti-CD20 monoclonal antibody, ublituximab, for the treatment of lymphoma.

Overall, Checkpoint Therapeutics' mission is to develop innovative immunotherapy treatments that can improve outcomes for patients with cancer. The company's emphasis on targeting PD-L1 and VISTA makes it well-positioned to continue making progress in the fight against cancer.


   Company Address: 95 Sawyer Road Waltham 2453 MA
   Company Phone Number: 652-4500   Stock Exchange / Ticker: NASDAQ CKPT
   CKPT is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market: Funding Boost for Promising Immunotherapy and Targeted Oncology Research

Published Mon, Jan 29 2024 1:01 PM UTC

Checkpoint Therapeutics Inc., a clinical-stage immunotherapy and targeted oncology company, has recently made an exciting announcement regarding its latest financial development. The company has officially entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of 7,756,233 shares of its common stock at a purcha...

Clinical Study

FDA Supports Cosibelimab's Efficacy While Urging Fine-Tuning of Manufacturing Process for Approval

Published Mon, Dec 18 2023 12:01 PM UTC



In a recent development, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for cosibelimab, a promising drug under development for a range of medical conditions, including certain types of cancer. This letter is solely attributed to inspection findings at a third-party manufacturer, as the FDA did not express any concerns about...

Checkpoint Therapeutics Inc

Company's Profits Take a Dizzying Dive in Recent Fiscal Period - What's Next for Checkpoint Therapeutics Inc?



As the fiscal third quarter of 2023 comes to a close, Checkpoint Therapeutics Inc, a prominent biopharmaceutical company, has recently released its financial results. While the company experienced certain setbacks, it also achieved significant progress in key areas of its operations. In this article, I will delve into the company's financial performance, shed light on noteworthy developments, and provide insights into the challenges it faces.
Financial Performance:
In the fiscal Q3 of 2023, Checkpoint Therapeutics Inc witnessed a significant expansion of losses, with a loss per share of $-0.29. This reflects a substantial increase from the loss of $-0.12 per share recorded in the same quarter last year. However, the company exhibited improvement in its earnings per share (EPS) compared to the preceding quarter, with a reported EPS of $-1.05 per share. These figures demonstrate the volatility inherent in the biopharmaceutical industry.

Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc Reports Further Enlarged Losses During the Second Quarter of 2023 Earnings Season


As the quarterly earnings season unfolds, the financial results of companies across various sectors are being closely scrutinized by investors and analysts. Among these, Checkpoint Therapeutics Inc's second-quarter earnings for 2023 have grabbed attention due to a mixed bag of developments.
First and foremost, the company witnessed a significant increase in its shortfall per share as it reported $-1.05 per share compared to $-0.16 a year ago. Moreover, when compared to the previous financial reporting period, there was a decline as the shortfall rose from $-0.89 per share.

Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc Struggles as Top-line Plunges in First Quarter of 2023 Earnings Season, Signaling Caution for Investors

As an investor in the stock market, it is important to proceed with caution when considering Checkpoint Therapeutics Inc. The company's revenue per employee has grown on a trailing twelve months basis, but it still lags behind the company average. Furthermore, when compared to its peers in the Healthcare sector, employees at 285 other companies have achieved higher revenue per employee.
Additionally, the company's overall ranking has deteriorated compared to the fourth quarter of 2022. In the first quarter of 2023, Checkpoint Therapeutics Inc recorded a loss per stock of $-0.89 per share, which is a significant increase from the $0.20 loss per share from the previous year and an even greater increase from the $-0.24 per share loss from the preceding quarter.






 

Checkpoint Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com